• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

DURECT Corporation focuses on the development of pharmaceutical products for pain, central nervous system disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. Its products include Remoxy, an oxycodone gelatin capsule for chronic pain, which is accepted as a new drug application; POSIDUR, a release formulation of bupivacaine that is under Phase III clinical trial for post operative pain; ELADUR, a transdermal bupivacaine patch, which is under Phase II clinical trial, provides continuous delivery of bupivacaine for up to three days from a single application, as well as for the treatment of pain associated with post-herpetic neuralgia; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch, which is under Phase II clinical trial, provides continuous delivery of sufentanil for a period of up to seven days from a single application. The company?s products also comprise oral controlled release opioid for pain that is under the Phase I clinical trial; and ORADUR-ADHD, a preclinical trial product targeting attention deficit hyperactivity disorder. It markets ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals. The company also develops and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. The company has strategic agreements with Alpharma Ireland Limited; Nycomed Danmark, ApS; Pain Therapeutics, Inc.; Endo Pharmaceuticals Inc; Curaxis Pharmaceutical Corporation; ALZA Corporation; EpiCept Corporation; NeuroSystec Corporation; and King Pharmaceuticals, Inc. DURECT Corporation was founded in 1998 and is based in Cupertino, California.

NO
     
DRRX (Durect Corp)
Last Trade 2.0 Date 1/24/2020
Change % -4.77 % Price Change -0.10
Open 2.11 52 Week High 3.949
High 2.13 52 Week Low 0.5
Low 1.925 Type stock
Volume 1593267 Average Volume 1366240
Prev Close 2.1 Stock Exchange NASDAQ
Bid 1.95 Ask 2.04
Bid Size 5 Ask Size 24
1st Yr Estimated EPS Growth 0.1429 2nd Yr Estimated EPS Growth -0.5
2 Years Forward Earning Yield -0.04 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.1144 Book Value Yield 0.0572
Buy Back Yield CAPE Ratio
Cash Return 0.0097 Cash Flow per Share 0.006
Cash Flow Yield 0.003 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.07 EV/EBIT
EV/EBITDA EV / Free Cash Flow 384.8251
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 14.5765 EV / Pre Tax Income
EV / Revenue 15.7993 EV / Total Asset 4.0289
Expected Dividend Growth Rate Free Cash Flow per Share 0.0054
Free Caash Flow Ratio 368.441558 Free Cash Flow Yield 0.0027
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.08 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 17.482703 PB Ratio 10 Year Growth 0.097454
PB Ratio 3 Year Growth 16.206132 Cash Ratio 3 Year Average 614.6561
Price to Cash Flow Ratio 332.136585 PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 5.187642 PE Ratio 10 Year Growth
PE Ratio 10 Year High 8.722222 PE Ratio 10 Year Low 3.305238
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 340.506421 Price Change 1 Month 0.526316
Price to Cash Ratio 6.754171 Price / EBITDA
Price to Sales Ratio 15.126633 Price to Sales Ratio 10 Year Growth 0.072867
Price to Sales Ratio 3 Year Avg 8.339747 Price to Sales Ratio 5 Year Avg
Sale per Share 0.1322 Sales Yield 0.0661
Sustainable Growth Rate -0.9832 Tangible Book Value per Share 0.0811
Tangible Book Value per Share 3 year Avg 0.0756 Tangible Book Value per Share 5 year Avg 0.0724
Total Asset per Share 0.4588 Total Yield
Working Capital per Share 0.1718 Working Capital per Share 3 Year Avg 0.1657
Working Capital per Share 5 Year Avg 0.1925 Beta 1.504533